The concept of Biological Variation (BV) has been known for many years, with several excellent reviews and books published on the subject. 1--3 BV is a component of the total variation (CV T ) and can be considered in terms of intra-individual (BV I ) and inter-individual (BV G ) variation. For a given individual the BV I can be determined from the total variation (CV T ) and the analytical variation (CV A ). Since the CV A can be readily calculated for most analytes the BV I can be readily determined. BV I should re£ect 'random' variation; it should be independent of method and analytical variance. Non-random variations such as e¡ects of diet, menstrual cycle, seasonal variation, age, sex, etc, must be taken into account before the BV is determined. Preanalytical variables, such as collection tube type, sampling technique, etc, also need to be minimized to enable an accurate BV I to be determined.
In this edition of the Annals of Clinical Biochemistry, Carmen Rico Ł s and colleagues 4 refer to their previously established database which lists BV 1 and BV G for many analytes (http://www.westgard.com/biodatabase1.htm). They took care in the compilation of the data base to ensure that the BV were all determined taking into account the non-random and pre-analytical variables and employing the correct statistical analysis on the appropriate numbers of samples and subjects. In this way they have produced a database of mean BVs which can be used to help in the determination of reference ranges and the calculation of what are signi¢cant changes in an analyte, termed the Reference Change Value (RCV), a vital component when monitoring patients.
The RCV for any analyte is usually determined on healthy individuals. Carmen Rico Ł s and colleagues 4 ask if the RCV was the same in disease as it is in health. If the RCV does change in disease, this will have a fundamental bearing on how we determine what are clinically signi¢cant changes when monitoring patients.
From their literature review, we can be reassured that the majority of BVs remain the same in disease as in health. Using PSA as an example, 5 the BV has been shown to be the same in healthy men and in those with stable prostate cancer. Employing the BV I in healthy men along with average CV A for the majority of PSA assays commercially available, a change of PSA of 50% or greater can be considered clinically signi¢cant. This ¢gure is commonly used by laboratories and clinicians. For each analyte the BV I was higher in the disease state than in health, and furthermore, it was the index disease which was the BV variant; for example HbA 1c in diabetes. The authors state that if the BV does di¡er in health and disease, we need to employ di¡erent RCV than those normally used. Before we move forwards such a plan perhaps we need to re£ect upon what BV is and why should it vary in health and disease?
BV is random variation, and for each analyte it would be made up of di¡erent factors. For example, with PSA the random variation could be due to variations in cell turnover, PSA synthesis and clearance from the blood. Clearly these factors could be altered in the disease state, but would they become more variable for an individual? Theoretically it may be possible that the increased size of a prostate gland and/or the greater number of cells producing PSA could make them more susceptible to large changes due to possible 'random' events which may stimulate the release of PSA into the bloodstream. In practice this does not appear to be a problem. 5 Similar logic may be applied to the analytes discussed Rico Ł s's article. 4 However, considering the clinical consequences of adopting disease-speci¢c RCVs, we need to be certain that they are credible.
Many factors will in£uence the calculation of CV I and this may be re£ected in the wide ranges of CV I that have been determined for any analyte. The number of measurements, frequency, time span over which the measurements have been made plus the total number of individuals assessed could all in£uence the determination of average CV I being determined. Once again taking PSA as an example, the BV I varies from 2.1 to 22.9%. 5 It has been suggested that these variations in BV are important when assessing serum lipids 6 and hsCRP. 7 Other factors may a¡ect CV I --for example, the degree of cross-reactivity in immunoassays, or noncreatinine interferences in the Ja¡e Ł reaction, especially at the bottom end of the measured values. Is it possible to compare average BV from several studies to a BV determined in disease?
Finally, as with all these types of studies there will always be the problem of deciding when and for how long a disease is stable.
Due to all these uncertainties, before we adopt disease-speci¢c RCVs the CV I in health and disease, carefully controlled experiments employing identical pre-analytical, analytical and well matched patients and controls will be required. It is hoped that Rico Ł s and colleagues continue to re¢ne their exceedingly useful database, and we may ¢nd we can lower the variation in BV in both health and disease.
